多发性骨髓瘤治疗最新进展：第53届美国血液学会年会报道

Report on recent progress of multiple myeloma in the 53rd annual meeting of American Society of Hematology

第53届美国血液学会年会于2011年12月在美国圣地亚哥市召开，大会针对多发性骨髓瘤的诊治报道了大量最新的研究进展。在治疗方面，沙利度胺、来那度胺、硼替佐米等作为一线治疗药物，已经取得可喜的疗效；pomalidomide作为新一代的免疫调节剂，获得良好的疗效，有望成为一线的治疗药物；苯达莫司汀为基础的方案针对肾功能不全和复发、难治的骨髓瘤患者具有一定的疗效；自体干细胞移植对年轻的多发性骨髓瘤患者仍然是维持治疗的首选方案，能延长患者的无疾病进展生存期和总生存期；同样其他类型的新药正逐步进入临床试验，具有很好的应用前景。

The 53rd ASH meeting was held in San Diego in December 2011. The meeting has received many advanced reports on the diagnosis and treatment of multiple myeloma （MM）. On therapy, with the application of thalidomide, lenalidomide and bortezomib as inductive treatments, the clinical outcomes have been improved greatly in MM patients. Pomalidomide, a new immunomodulator, can be hopefully used as a frontline medicine for MM because of its high response. Bendamustine combination with other treatments induced efficient response and good response rates in MM patients with renal insufficiency or relapse~ refactory disease. Currently autologous stem cell transplantation is still the standard care for newly diagnosed young MM patients. At this time other kinds of novel agents have entered into clinical trials and have shown a bright future of application.